Stocks Health care NGEN
NASDAQ · Health careNervgen Pharma Corp. (NGEN)
It posted a net loss of CA$44.1M. At December 31, 2025 it held CA$22.1M in cash. Its latest periodic report to the SEC is the annual report (Canadian issuer) (40-F) filed on March 31, 2026.
What Nervgen Pharma Corp. does
Nervgen Pharma Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NGEN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -CA$44.1M | -CA$0.61 | n/a |
| 2025 | n/a | -CA$24.3M | -CA$0.36 | n/a |
Latest SEC filings
What Nervgen Pharma Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 24, 2026
- August 13, 2026
- July 2, 2026
- July 2, 2026Form SUPPL filing SUPPL
- June 1, 2026
- May 26, 2026
- May 26, 2026Form SUPPL filing SUPPL
- May 26, 2026Form F-X filing F-X
- May 26, 2026Form F-10 filing F-10
Questions about NGEN
What does Nervgen Pharma Corp. do?
Nervgen Pharma Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NGEN.
Is Nervgen Pharma Corp. profitable?
No. In fiscal 2025 it reported a net loss of CA$44.1M.
When did Nervgen Pharma Corp. last report?
Its most recent periodic report is the annual report (Canadian issuer) (40-F) filed on March 31, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 25, 2026.
Similar companies
Follow NGEN
Get an email when Nervgen Pharma Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Follow NGEN: get an email when it filesWhere the numbers come from
Financial figures are the values Nervgen Pharma Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.